Paclitaxel-Coated Stents and Balloons May Increase Risk Of Death, FDA Warns

Irvin Jackson

Add Your Comments

While the U.S. government remains shutdown, federal regulators issued a warning on Thursday that indicates medical stents and balloons coated with paclitaxel could be linked to an increased risk of death. 

The FDA issued a letter to health care providers on January 17, announcing that the agency is investigating paclitaxel-coated balloons and paclitaxel-eluting stents used for the treatment of peripheral arterial disease (PAD). The safety review comes following a recent study that suggests the devices were linked to an increased risk of mortality.

The study was published last month in the Journal of the American Heart Association, and found an increased mortality rate among patients given the drug-coated devices to treat PAD when compared to patients given bare balloons and stents.

Do You Know about…

Spinal Cord Stimulator lawsuits

Spinal cord stimulator lawsuits are being investigated for individuals who suffered unnecessary shocks, burns or other problems, often resulting in the need for additional surgery to remove the SCS.

Learn More
SEE IF YOU QUALIFY FOR COMPENSATION
Spinal-Cord-Stimulation-Lawsuit
Spinal-Cord-Stimulation-Lawsuit

Do You Know About…

Spinal Cord Stimulator lawsuits

Spinal cord stimulator lawsuits are being investigated for individuals who suffered unnecessary shocks, burns or other problems, often resulting in the need for additional surgery to remove the SCS.

Learn More
SEE IF YOU QUALIFY FOR COMPENSATION

The devices are meant to treat lesions in the femoropopliteal artery, opening up the obstructed vessel. When coated with paclitaxel, the drug prevents scar tissue formation. The meta-analysis, conducted by researchers from Greece, did not indicate why the drug was increasing the risk of death for recipients.

The FDA announced it will evaluate this study and other available long-term follow-up data to determine if paclitaxel-coated products present any long-term health risks. Currently, the agency’s stance is that the benefits of these products outweigh the potential risks, but the FDA will issue more information to the public as it becomes available.

“This review will focus on causes of death, the paclitaxel dose delivered, and patient characteristics that may impact clinical outcomes. Additional statistical analyses will be performed to clarify the presence and magnitude of any long-term risks,” the agency states. “We are working with manufacturers of paclitaxel-coated balloons and paclitaxel-eluting stents to better understand this issue.”

In the meantime, the FDA is recommending that health care providers take a number of steps, including:

  • Continued surveillance of patients implanted with paclitaxel-coated balloons and paclitaxel-eluting stents.
  • Discussing the risks and benefits of all available treatment options for peripheral arterial disease with patients.
  • Reporting any adverse events linked to the drug-coated balloons and stents to the FDA’s MedWatch Adverse Event Reporting Program.
Irvin Jackson
Written by: Irvin Jackson

Senior Legal Journalist & Contributing Editor

Irvin Jackson is a senior investigative reporter at AboutLawsuits.com with more than 30 years of experience covering mass tort litigation, environmental policy, and consumer safety. He previously served as Associate Editor at Inside the EPA and contributes original reporting on product liability lawsuits, regulatory failures, and nationwide litigation trends.

Tags: Drug Eluting Stent, Paclitaxel

More Lawsuit Stories

0 Comments

This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

JPML Sets Hearing Over Spinal Cord Stimulator Lawsuit Consolidation For May 28
In late May, a panel of federal judges will hold oral arguments over whether all federal spinal cord stimulator lawsuits should be consolidated before one judge for pretrial proceedings.
Fire Pit Burn Lawsuits Mount as CPSC Issues Warning Over New Flame Jetting Injuries, Death
As the number of lawsuits over tabletop fire pits continues to grow, the CPSC has issued a warning indicating that despite a consumer’s death linked to one product, the manufacturer has not agreed to remove the devices from the market.
Depo-Provera Meningioma Warning Update Should Be Added to Birth Control Shot Lawsuit
A Depo-Provera meningioma lawsuit argues that Pfizer had a duty to warn women about scientific evidence linking the birth control shot to potential brain tumor growth yet failed to do so.